<DOC>
	<DOCNO>NCT01763918</DOCNO>
	<brief_summary>The primary objective evaluate effect 12 week evolocumab subcutaneously every 2 week ( Q2W ) monthly ( QM ) , compare placebo , percent change baseline low-density lipoprotein cholesterol ( LDL-C ) adult heterozygous familial hypercholesterolemia ( HeFH ) .</brief_summary>
	<brief_title>Reduction LDL-C With PCSK9 Inhibition Heterozygous Familial Hypercholesterolemia Disorder Study-2</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Male female ≥ 18 ≤ 80 year age Diagnosis heterozygous familial hypercholesterolemia On stable dose approve statin lipid regulate medication Fasting LDLC ≥ 100 mg/dL ( 2.6 mmol/L ) Fasting triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) Homozygous familial hypercholesterolemia LDL plasma apheresis New York Heart Association ( NYHA ) III IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Type 1 diabetes , poorly control type 2 diabetes Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High cholesterol , Treatment high cholesterol , Lowering cholesterol , Lowering high cholesterol , Hypercholesterolemia</keyword>
</DOC>